Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress

Tricuspid regurgitation (TR) is a complex disease with several independent causes. Consequently, outcomes and response to therapy vary widely. Severe or progressive TR often results in gradual right ventricular (RV) failure and is associated with poor long-term outcomes.1 Most cases ...

Cardiogenic shock (CS) is a life-threatening condition characterized by cardiac pump dysfunction resulting in end-organ hypoperfusion and hypoxia.1,2 Although multiple treatment strategies have been explored in clinical trials, optimal therapy for CS is still debatable and mortality remains substantially high ...

Transcatheter-based therapies have become central to the treatment of valvular heart disease, particularly aortic stenosis.1–5 The first transcatheter aortic valve replacement (TAVR) was performed in 2002 and, in two short decades, TAVR has become a mainstay for the treatment of aortic ...

Drug-eluting technology is a widely accepted, proven treatment for coronary artery stenosis and occlusions, with superior results when compared with bare metal stents or plain old balloon angioplasty (POBA).1,2 Many studies also proved drug-eluting stents (DES) and drug-coated balloons (DCB) ...

Lead displacement in pacemakers is a common implantation-related procedural complication, often resulting in prolonged hospital stays for patients and increased healthcare costs.1,2 The frequency of long-term lead displacement ranges between 1.8% and 8.0%.3,4 Recognizing lead displacement complications is an essential part of ...

Transcatheter aortic valve replacement (TAVR) has seen worldwide explosive growth. The current USA guidelines no longer use risk in choosing between TAVR and surgical aortic valve replacement, and the European guidelines have extended the recommendation for TAVR to lower risk ...

Background: The way that dual chamber pacemakers are programmed can affect the estimated battery longevity. This remaining battery life is calculated by the device itself; it is unknown how specific variables such as reduced ventricular pacing modes/algorithms and rate ...

Introduction: Over the past 10 years, the indications for implantable loop recorder (ILR) have broadened and the device size has reduced substantially. The implant procedure has moved from the physician-led catheter-lab environment to non-physician-led outpatient procedures. ILR explant procedures have not ...

Introduction: The use of remote monitoring (RM) to undertake cardiac implantable electronic device (CIED) follow-up is becoming increasingly common, particularly following the COVID-19 pandemic. This method of CIED assessment has been shown to be non-inferior to face-to-face only assessments. Purpose: ...

Introduction: Implantable cardiac defibrillators (ICDs) are a lifesaving therapy for children at risk of life-threatening arrhythmias. Often, such children will present with sudden cardiac arrest, and ICDs are vital for secondary prevention of further life-threatening events. If high-risk young patients ...

Introduction: Medical therapy for heart failure with reduced ejection fraction (HfrEF) improves quality of life, reduces heart failure hospitalization and mortality, and reduces the risk of ventricular arrhythmias. International guidelines recommend four key drug classes for all patients with HfrEF. ...

Inappropriate implantable cardioverter-defibrillator (ICD) therapies are associated with adverse outcomes. The aim of this study is to determine the frequency and cause of inappropriate therapies in patients under the care of Royal Papworth Hospital NHS Foundation Trust, UK. All patients ...